Patents by Inventor Makoto Kitade
Makoto Kitade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10174040Abstract: A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof.Type: GrantFiled: February 7, 2018Date of Patent: January 8, 2019Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Takashi Mizutani, Chihoko Yoshimura, Hitomi Kondo, Makoto Kitade, Shuichi Ohkubo
-
Publication number: 20180162864Abstract: A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof.Type: ApplicationFiled: February 7, 2018Publication date: June 14, 2018Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Takashi MIZUTANI, Chihoko YOSHIMURA, Hitomi KONDO, Makoto KITADE, Shuichi OHKUBO
-
Patent number: 9963456Abstract: A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof.Type: GrantFiled: June 24, 2015Date of Patent: May 8, 2018Assignee: Taiho Pharmaceutical Co., LtdInventors: Takashi Mizutani, Chihoko Yoshimura, Hitomi Kondo, Makoto Kitade, Shuichi Ohkubo
-
Publication number: 20170066772Abstract: An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.Type: ApplicationFiled: June 24, 2015Publication date: March 9, 2017Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Takashi MIZUTANI, Chihoko YOSHIMURA, Hitomi KONDO, Makoto KITADE, Shuichi OHKUBO
-
Patent number: 9273045Abstract: It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X1 represents CH or N; any one of X2, X3 and X4 represents N, and the others represent CH; any one or two of Y1, Y2, Y3 and Y4 represent C—R4, and the others are the same or different and represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R2 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R3 and R4 represent —CO—R5 or the like.Type: GrantFiled: April 1, 2014Date of Patent: March 1, 2016Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto Kitade, Shuichi Ohkubo, Chihoko Yoshimura, Satoshi Yamashita, Hiromi Oshiumi, Takao Uno, Yuichi Kawai
-
Patent number: 9181183Abstract: The present invention provides a piperidine compound represented by Formula (I) (wherein X1, X2, X2, A, B and N are as defined in the Description); or a salt thereof.Type: GrantFiled: September 6, 2011Date of Patent: November 10, 2015Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Makoto Kitade, Keiko Yamane, Shinichi Aoki, Hiroyoshi Yamanaka
-
Patent number: 9120780Abstract: The invention provides an indazole compound of formula (I) which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells:Type: GrantFiled: January 6, 2012Date of Patent: September 1, 2015Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto Kitade, Shuichi Ohkubo, Chihoko Yoshimura
-
Patent number: 9062035Abstract: This invention relates to a piperazine compound represented by Formula (I), wherein R1 is c1-6 alkyl; R2 is hydroxy, c1-6 alkyl that may have one or more substituents, —(C?O)—N(R2)(R4), or —(C?O)—OR5; R3 and R4 are the same or different, and each represents hydrogen or c1-6 alkyl that may have one or more substituents, or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; R5 is hydrogen or c1-6 alkyl that may have one or more 15 substituents; and n is 1 or 2; or a salt thereof.Type: GrantFiled: January 8, 2014Date of Patent: June 23, 2015Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Makoto Kitade, Kazuhiko Shigeno, Keiko Yamane, Katsunao Tanaka
-
Patent number: 8912181Abstract: A novel bicyclic compound having an HSP90 inhibitory effect and a carcinostatic effect. A pharmaceutical agent based on the HSP90 inhibitory effect and useful in the prevention and/or treatment of a disease involving HSP90, particularly cancer. The compound has a general formula (I) or is a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are each independently C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are each independently CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R3 represents a hydrogen atom, —CO—R5 etc.Type: GrantFiled: January 6, 2012Date of Patent: December 16, 2014Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Makoto Kitade, Satoshi Yamashita, Shuichi Ohkubo
-
Patent number: 8865714Abstract: This invention relates to a piperazine compound represented by Formula (I), wherein R1 is C1-6 alkyl; R2 is hydroxy, C1-6 alkyl that may have one or more substituents, —(C?O)—N(R3)(R4), or —(C?O)—OR5; R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents, or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; R5 is hydrogen or C1-6 alkyl that may have one or more substituents; and n is 1 or 2; or a salt thereof.Type: GrantFiled: March 8, 2010Date of Patent: October 21, 2014Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Makoto Kitade, Kazuhiko Shigeno, Keiko Yamane, Katsunao Tanaka
-
Publication number: 20140303162Abstract: It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X1 represents CH or N; any one of X2, X3 and X4 represents N, and the others represent CH; any one or two of Y1, Y2, Y3 and Y4 represent C—R4, and the others are the same or different and represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R2 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R3 and R4 represent —CO—R5 or the like.Type: ApplicationFiled: April 1, 2014Publication date: October 9, 2014Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto KITADE, Shuichi Ohkubo, Chihoko Yoshimura, Satoshi Yamashita, Hiromi Oshiumi, Takao Uno, Yuichi Kawai
-
Patent number: 8779142Abstract: It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X1 represents CH or N; any one of X2, X3 and X4 represents N, and the others represent CH; any one or two of Y1, Y2, Y3 and Y4 represent C—R4, and the others are the same or different and represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R2 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R3 and R4 represent —CO—R5 or the like.Type: GrantFiled: July 9, 2010Date of Patent: July 15, 2014Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Makoto Kitade, Shuichi Ohkubo, Chihoko Yoshimura, Satoshi Yamashita, Hiromi Oshiumi, Takao Uno, Yuichi Kawai
-
Patent number: 8765750Abstract: The present invention provides a piperazine compound represented by Formula (I) or a salt thereof, wherein X represents CH or an N atom; R1 represents C1-6 alkyl; R2 represents C1-6 alkyl that may have one or more substituents, C2-6 alkenyl that may have one or more substituents, —(C?O)—N(R3)(R4), or —(C?O)—OR5, R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents; or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; and R5 represents hydrogen or C1-6 alkyl that may have one or more substituents or aralkyl.Type: GrantFiled: January 19, 2011Date of Patent: July 1, 2014Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Makoto Kitade, Kazuhiko Shigeno, Keiko Yamane, Katsunao Tanaka
-
Publication number: 20140128394Abstract: This invention relates to a piperazine compound represented by Formula (I), wherein R1 is c1-6 alkyl; R2 is hydroxy, c1-6 alkyl that may have one or more substituents, —(C=0)-N(R2)(R4), or —(C=0)-0R5; R3 and R4 are the same or different, and each represents hydrogen or c1-6 alkyl that may have one or more substituents, or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; R5 is hydrogen or c1-6 alkyl that may have one or more 15 substituents; and n is 1 or 2; or a salt thereof.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro URADE, Makoto KITADE, Kazuhiko SHIGENO, Keiko YAMANE, Katsunao TANAKA
-
Publication number: 20130296320Abstract: Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R3 represents a hydrogen atom, —CO—R5 etc.; R4 represents a hydrogen atom, —CO—R6, —N(R7)(R8) etc.Type: ApplicationFiled: January 6, 2012Publication date: November 7, 2013Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto Kitade, Satoshi Yamashita, Shuichi Ohkubo
-
Publication number: 20130289072Abstract: The present invention relates to provision of a novel indazole compound which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells. The present invention also relates to provision of a drug useful for preventing and/or treating, on the basis of an HSP90 inhibitory effect, a disease in which HSP90 participates, in particular, cancer. A compound represented by the general formula (I) or a salt thereof: wherein X represents CH or N; any one or two of Y1, Y2, Y3, and Y4 represent C—R3 or N, and the others represent CH; A and B are the same or different and represent an optionally substituted monocyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R1 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R2 represents a hydrogen atom, a halogen atom etc.; R3 represents a hydrogen atom, a halogen atom etc.; R4 and R5 are the same or different and represent a hydroxyl group etc.Type: ApplicationFiled: January 6, 2012Publication date: October 31, 2013Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto Kitade, Shuichi Ohkubo, Chihoko Yoshimura
-
Publication number: 20130165438Abstract: The present invention provides a piperidine compound represented by Formula (I) (wherein X1, X2, X2, A, B and N are as defined in the Description); or a salt thereof.Type: ApplicationFiled: September 6, 2011Publication date: June 27, 2013Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro Urade, Makoto Kitade, Keiko Yamane, Shinichi Aoki, Hiroyoshi Yamanaka
-
Publication number: 20120309760Abstract: The present invention provides a piperazine compound represented by Formula (I) or a salt thereof, wherein X represents CH or an N atom; R1 represents C1-6 alkyl; R2 represents C1-6 alkyl that may have one or more substituents, C2-6 alkenyl that may have one or more substituents, —(C?O)—N(R3)(R4), or —(C?O)—OR5, R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents; or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; and R5 represents hydrogen or C1-6 alkyl that may have one or more substituents or aralkyl.Type: ApplicationFiled: January 19, 2011Publication date: December 6, 2012Applicant: Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Makoto Kitade, Kazuhiko Shigeno, Keiko Yamane, Katsunao Tanaka
-
Publication number: 20120108589Abstract: It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X1 represents CH or N; any one of X2, X3 and X4 represents N, and the others represent CH; any one or two of Y1, Y2, Y3 and Y4 represent C—R4, and the others are the same or different and represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R2 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R3 and R4 represent —CO—R5 or the like.Type: ApplicationFiled: July 9, 2010Publication date: May 3, 2012Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Makoto Kitade, Shuichi Ohkubo, Chihoko Yoshimura, Satoshi Yamashita, Hiromi Oshiumi, Takao Uno, Yuichi Kawai
-
Publication number: 20110319413Abstract: This invention relates to a piperazine compound represented by Formula (I), wherein R1 is C1-6 alkyl; R2 is hydroxy, C1-6 alkyl that may have one or more substituents, —(C?O)—N(R3)(R4), or —(C?O)—OR5; R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents, or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; R5 is hydrogen or C1-6 alkyl that may have one or more substituents; and n is 1 or 2; or a salt thereof.Type: ApplicationFiled: March 8, 2010Publication date: December 29, 2011Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro Urade, Makoto Kitade, Kazuhiko Shigeno, Keiko Yamane, Katsunao Tanaka